{"id":48210,"date":"2022-09-11T09:01:42","date_gmt":"2022-09-11T07:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/"},"modified":"2022-09-11T09:01:42","modified_gmt":"2022-09-11T07:01:42","slug":"new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/","title":{"rendered":"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer"},"content":{"rendered":"
\n

\nFindings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer<\/i>\n<\/p>\n

\nData support Veracyte\u2019s plan to expand test availability in the U.S. and offer test globally <\/i>as an in vitro diagnostic<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc<\/a>. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company\u2019s Decipher Prostate Genomic Classifier to identify men with advanced prostate cancer who are more likely to benefit from intensified treatment with abiraterone acetate and prednisolone (AAP) in addition to standard-of-care androgen-deprivation therapy (Abstract #13580<\/a>). The findings were shared in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022 and support the company\u2019s continued expansion of its high-value genomic tests for patients in the United States and globally.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThere are an increasing number of treatment options available for men with advanced prostate cancer, and the challenge for physicians is determining the best treatment combination for the right patient,\u201d said Gerhardt Attard, M.D., Ph.D., group leader of the Treatment Resistance Research Group at the University College London Cancer Institute, and STAMPEDE study co-investigator. \u201cOur findings show that the Decipher Prostate Genomic Classifier \u2013<\/i> and tumor transcriptomes in general \u2013<\/i> can provide robust and clinically relevant prognostic information that may help guide important decisions about the treatment of advanced prostate cancer. Most notably, this study has identified patients who have poor prognoses and benefit greatly from addition of hormone treatment tablets, while other men have a good prognosis and may be able to avoid the toxicities of treatment.\u201d\n<\/p>\n

\nThe Decipher Prostate classifier is a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient\u2019s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment.\n<\/p>\n

\nThe STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer<\/i>: Evaluation of Drug Efficacy) protocol involves more than 10,000 men to date with high-risk, non-metastatic (M0) or metastatic (M1) prostate cancer who are starting long-term androgen-deprivation therapy (ADT) for the first time and are randomized to new treatments in (to date) seven Phase 3 trials. In this post-hoc analysis of the abiraterone acetate trial, Prof. Attard and colleagues evaluated the prognostic ability of the Decipher Prostate test among 781 men who were randomized to receive standard-of-care ADT with or without abiraterone acetate and prednisolone (AAP). They found that Decipher was prognostic in both the M0 and M1 patients, with higher Decipher scores associated with worse overall survival in M1 patients, and worse metastasis-free survival in M0 patients. Additionally, study findings suggest that men with high Decipher scores who received AAP had the greatest improvement in outcomes, while those with low Decipher scores received less absolute oncologic benefit from the addition of AAP.\n<\/p>\n

\n\u201cThe Decipher Prostate classifier is the most validated genomic test in prostate cancer, and this analysis suggests that we may be able to further expand its use to help inform often-challenging decisions regarding intensification of therapy in men with advanced prostate cancer,\u201d said Elai Davicioni, Ph.D., Veracyte\u2019s medical director, Urology. \u201cWe are honored to be working with leading prostate cancer researchers around the world to help further advance precision medicine.\u201d\n<\/p>\n

\n\u201cThese findings, from one of the most important prostate cancer clinical trials of this era, further underscore our commitment to clinical rigor and innovation in our efforts to improve patient outcomes in prostate and other cancers,\u201d said Marc Stapley, Veracyte\u2019s CEO. \u201cThey also further support our plan to deliver our high-value tests, including the Decipher Prostate Genomic Classifier, to patients around the world.\u201d\n<\/p>\n

\nAmong the other abstracts presented at the ESMO conference, researchers shared data derived from Veracyte\u2019s Decipher GRID, a database of more than 100,000 whole-transcriptome profiles from patients with urologic cancers. Decipher GRID has led to the discovery or development of more than 400 genomic signatures that can be leveraged to help advance understanding of prostate and other urologic cancers, as well as to support biopharmaceutical companies\u2019 targeted-therapy development programs.\n<\/p>\n

\nIn a poster presentation today (Abstract #1381P), researchers shared data showing that the Decipher GRID androgen receptor activity (AR-A) signature is prognostic for outcomes in men with castration-sensitive prostate cancer (CSPC) that has spread to no more than three other sites in the body (oligometastatic CSPC, or omCSPC). The researchers concluded that the GRID AR-A signature is prognostic for outcomes in men with omCSPC treated with metastasis-directed therapy (MDT, or radiotherapy) and that patients with a low AR-A score receive the most benefit from the addition of ADT to MDT.\n<\/p>\n

\nAbout Veracyte<\/b>\n<\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument (nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: \u201cappears,\u201d “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” \u201cpositioned,\u201d \u201cdesigned\u201d and similar references to future periods. An example of a forward-looking statements include, among others, that data presented at the ESMO Congress may help expand availability of our Decipher Prostate Genomic Classifier and that the Decipher Prostate Genomic Classifier may help to identify men with advanced prostate cancer who are more likely to benefit from intensified treatment. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q to be filed for the three months ended June 30, 2022. Copies of these documents, when available, may be found in the Investors section of our website at www.investor.veracyte.com<\/a>. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.\n<\/p>\n

\nVeracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.\n<\/p>\n

\nVeracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Shayla Gorman
\n
Director, Investor Relations
\n
investors@veracyte.com<\/a>
619-393-1545\n<\/p>\n

\nMedia:<\/b>
Tracy Morris
\n
Vice President of Global Corporate Communications
\n
tracy.morris@veracyte.com<\/a>
650-380-4413\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte\u2019s plan to expand test availability in the U.S. and offer test globally as an in vitro diagnostic SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48210","6":"format-standard","7":"category-industry"},"yoast_head":"\nNew Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte\u2019s plan to expand test availability in the U.S. and offer test globally as an in vitro diagnostic SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-11T07:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220910005029\/en\/1567707\/21\/4715802cVeracyte_RGB_LRG_H.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer\",\"datePublished\":\"2022-09-11T07:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/\"},\"wordCount\":1265,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005029\\\/en\\\/1567707\\\/21\\\/4715802cVeracyte_RGB_LRG_H.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/\",\"name\":\"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005029\\\/en\\\/1567707\\\/21\\\/4715802cVeracyte_RGB_LRG_H.jpg\",\"datePublished\":\"2022-09-11T07:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005029\\\/en\\\/1567707\\\/21\\\/4715802cVeracyte_RGB_LRG_H.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005029\\\/en\\\/1567707\\\/21\\\/4715802cVeracyte_RGB_LRG_H.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer - Pharma Trend","og_description":"Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data support Veracyte\u2019s plan to expand test availability in the U.S. and offer test globally as an in vitro diagnostic SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-11T07:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220910005029\/en\/1567707\/21\/4715802cVeracyte_RGB_LRG_H.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer","datePublished":"2022-09-11T07:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/"},"wordCount":1265,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220910005029\/en\/1567707\/21\/4715802cVeracyte_RGB_LRG_H.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/","url":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/","name":"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220910005029\/en\/1567707\/21\/4715802cVeracyte_RGB_LRG_H.jpg","datePublished":"2022-09-11T07:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220910005029\/en\/1567707\/21\/4715802cVeracyte_RGB_LRG_H.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220910005029\/en\/1567707\/21\/4715802cVeracyte_RGB_LRG_H.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/new-data-presented-at-esmo-2022-show-veracytes-decipher-prostate-genomic-classifier-may-help-inform-personalized-treatment-decisions-in-men-with-advanced-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"New Data Presented at ESMO 2022 Show Veracyte\u2019s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48210"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48210\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}